Shares of Triangle Pharmaceuticals closed up 8 cents, to $2.64, today on the Nasdaq (symbol: VIRS) as Triangle announced positive tests for hits once-a-day AIDS drug Coviracil.

Triangle outlined data that said Coviracil was “statistically superior” to another AIDS drug, Zerit, at the 42nd annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

A New Drug Application for Coviracil was submitted to the FDA on Sept. 3.